Concord Wealth Partners Astrazeneca PLC Transaction History
Concord Wealth Partners
- $603 Million
- Q4 2024
A detailed history of Concord Wealth Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Concord Wealth Partners holds 2,271 shares of AZN stock, worth $169,620. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,271
Previous 2,221
2.25%
Holding current value
$169,620
Previous $173,000
14.45%
% of portfolio
0.02%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding AZN
# of Institutions
1,357Shares Held
512MCall Options Held
6.08MPut Options Held
4.44M-
Price T Rowe Associates Inc Baltimore, MD60.4MShares$4.51 Billion0.46% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$3.06 Billion2.12% of portfolio
-
Capital International Investors Los Angeles, CA37.5MShares$2.8 Billion0.48% of portfolio
-
Wellington Management Group LLP Boston, MA37MShares$2.77 Billion0.46% of portfolio
-
Bank Of America Corp Charlotte, NC24MShares$1.79 Billion0.13% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $231B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...